life-saving platform optimizing organ utilization...why you should invest in omnilife 20...
TRANSCRIPT
Maximizing The Gift of Life
Life-saving Platform Optimizing Organ Utilization
OmniLife Milestones Achieved to Date
✓Awarded $500k NIH SBIR grants & other non-dilutive funds
✓Syndicated $1M of $2M target Series A round (current offering)
✓Built a strong team with success exiting prior health IT startups
✓Finalized product R&D and launched commercial operations
✓Generated initial sales revenue with top U.S. hospitals
✓Facilitated more than 360 life-saving transplants
Connected Purpose to Transplant
Eric Pahl Health Informatics Doctoral Candidate
Three aunts fighting liver failure in need of transplant
FORBES 30 UNDER 30 CLASS OF 2018
Dalton Shaull Former University of Iowa football player
Nerve transplant recipient + Uncle Transplant Surgeon
FORBES 30 UNDER 30 CLASS OF 2018
Maximizing The Gift of Life
Organ Transplant Problem: Significant Waste Leads to Tragedy
* United Network for Organ Sharing 2014
54% Of Donated Organs Go Unused
Americans begin dialysis every year.
>100k
Kidney Disease and Dialysis
patients listed die within the first year
¼
Americans suffer from kidney disease
(CKD/ESRD)
>30M
Total Medicare spending on CKD/ESRD
$113B
Economic Impact of Kidney Disease
U.S. Gov. spends on our Medicare/Medicaid
budget
$1 out $5
Communication Breakdowns = Lost Time = Expired Organs
DONOR
(Raw Materials)
DONOR HOSPITAL (DH)
(Supplier)
ORGAN PROCUREMENT
ORGANIZATION (OPO)
(Distribution/Facilitator of Harvest)
TRANSPLANT CENTERS (TC)
(Customer/Reseller)
PATIENT/RECIPIENT
(Consumer)
× 500+ phone calls/transplant
× 40+ clinicians/coordinators
× Inefficient organ offering/allocation
× Non-HIPAA-compliant
Universal Communication Platform
✓Cost Reduction: Offsets expensive 3rd party call centers through automation and collaborative chat room teams
✓Cost Avoidance: Trackable, auditable, meets
industry standards nationwide. HIPAA compliant
✓Revenue Generating: Detailed reporting to
maximize reimbursement. ✓ Improve Outcomes: Proprietary data and
algorithms to provide real-time graft survival predictions
Recipient Data
Surgeon Data
Donor Data
Proven Value: NIH-SBIR Phase I
1 year study – 3 hospitals – 100+ transplants
Engagement: (+) 300%
Time on phone: (-) 50%
Organs Transplanted:
(+) 26%
Proven Value Proposition
Transplant Centers Organ Procurement
Organizations
Patients
Donor Hospitals
Tissue Processors/Banks
Medical Couriers
Dialysis Centers
/ Nephrologists
Living Donors
Current Customers
Potential Customers
Revenue Model
Phase 1: Hospital ‘SaaS’ Fee Phase 2: Hospital ‘Success’ Fee
$120,000 average per year per hospital
$5,000 per transplant
Fee Structure: SaaS Fee Structure: Transactional
› Provides access to ‘basic offering’ › Transplant Centers:
Billed as a “pre-
transplant expense”
› OPOs: Billed to TxC via the
”organ acquisition cost (OAC)”
› Gain access to “Ask Alan” AI
capability and other key features
*Significant Beta customer discounts offered 2018-2019
Phase 3: Patient ‘SaaS’ Fee
$300 per year per patient
Fee Structure: SaaS › Patients pay $25/month for wait-
list management, education, etc.
› Existing reimbursement in place
to cover this cost pre-transplant
› Ability to continue ‘out of pocket’
post transplant for medication
adherence / patient compliance
Hospital Size Annual Sales
Small Hospital $ 60,000
Medium Hospital $ 120,000
Large Hospital $ 240,000
$200M
$500M
$5B+
Large, Growing Market Opportunity
Phase 3: U.S. Patients (~1M patients on the wait list or approaching end-stage renal failure at $25/month or $300/yr/patient)
Phase 5: Global (Worldwide: All Organs & Tissues)
Phase 1+2: U.S. Hospitals SaaS + Transactional ($120k avg/hospital * Top 500 Hospitals Plus 30k transplants/yr. at $5k/each
1+2
3 4
5
Phase 4: Dialysis + Payors (US Gov. $42B/year on dialysis)
$1B+
Leadership Team
Eric Pahl, BSE, PhDc
Chief Technical Officer; Secretary (Co-Founder)
Strong connected purpose after
one of his aunts passed away
waiting for a life-saving organ
transplant in addition to 3 aunts still
waiting on critical transplants.
Eric is a doctoral fellow of health
informatics at University of Iowa
and provides technical expertise as
a computer scientist and
biomedical engineer. Eric also
brings previous health IT startup
experience at a medical imaging
and diagnostic company, IDx.
John Slump, BA
Chief Financial Officer; Treasurer
Serial health-tech entrepreneur with
10+ years CFO expertise at 4 startups
Exited a prior health IT startup after
growing concept to profitability
(TranslaCare acquired by Vertis)
Raised $50M+ for 3 med. device startups;
provided leadership from concept to FDA
approval and scaling sales worldwide
Cindy Edge, BSE
VP of Operations; Head of Software Engineering Team
Multifaceted senior IT/Telecom
professional with 25+ years of
experience leading engineering
operations and high-impact
software development organizations.
Former Principal at Rockwell Collins,
Worldcom, and McLeod USA focused
on intelligent communications systems
development and large-scale, strategic
integration. ‘
Greg Janes, BS, MBA
Chief Marketing Officer; Interim VP of Sales
Serial health-tech entrepreneur with
15+ years experience leading startups
pre-revenue to hyper sales growth
Helped lead 3 prior IT startups to
successful acquisitions; most recently,
(Telepharm acquired by Cardinal Health)
Dalton Shaull, BS
Chief Executive Officer; President (Co-Founder)
Strong connected purpose as a
transplant recipient with an uncle
who is a transplant surgeon.
Dalton brings experience as a
commercial employee at a
disruptive startup HLT, Inc., as
well as health technology
companies Stryker Medical and
DaVinci Robotics as a sales and
customer support representative.
Advisory Board
Manny Villafana, PhD
Business Advisor
Successful serial entrepreneur
with 7 successful IPO’s and
acquisitions in healthcare;
Founder of St. Jude Medical,
which employs 18,000 people
and was recently acquired
by Abbott for $25B.
Alan Reed, MD, MBA
Mai Le
Bob Emery, MD, FACC
Transplant Advisor
40+ years experience as a
practicing transplant surgeon
Founder and past President of an OPO,
LifeSource located in Minneapolis
Former Director of Thoracic Transplant
Program at Minneapolis Heart Institute.
Global key opinion leader in the
field of organ transplantation
Highly published and well-
respected authority in transplant
Transplant Advisor Technology Advisor
15+ years experience driving
organizational, cultural and technical
transformation across the corporation.
Senior leadership roles at Uber,
Yahoo, Walmart, Microsoft, Symantec
Current engineering leader at Uber
responsible for Business Platforms
Financial Projections
(in thousands) 2018(A) 2019(E) 2020(E) 2021(E) 2022(E) 2023(E)
Sales $30 $456 $2,884 $6,014 $11,398 $20,745
GM % 90% 84% 87% 88% 89% 90%
OPEX less grants $912 $1,314 $2,974 $4,305 $6,794 $9,307
EBITDA ($861) ($915) ($430) $1,024 $3,360 $9,346
Capital Raised $500 $1,500 $3,000 - - -
# of Employees (in ones)
10 13 23 30 40 50
Offering Amount: Up to $2M
Amount Committed: $1M
Valuation: $5.4M ($0.50/share)
Type of Security: Equity
Iowa Tax Credit: 25% tax credit–redeemable for out of state investors
Use of Proceeds: Grow Sales Revenues Hire more engineers & sales reps Advance R&D of additional product
Previous Investor(s): Bluegrass Angels Fund IV; Boston Harbor Angels; Iowa Lakes Capital; Dr. Villafaña (Founder St. Jude)
Current Financing Terms
17
Growing Investor Syndicate
Exit Strategy
19
Acquiree Acquirer Price ($ in millions)
Revenue ($ in millions)
Revenue
Multiple Year
HealthFusion Quality Systems, Inc. $190M $39M 5x 2015
Circulation Logisticare $57.5M Unknown Unknown 2018
Emmi Solutions Wolters $170M $28M 6x 2016
Advance Medical Teladoc $352M $63M 6x 2018
HealthGrid Allscripts $110M Unknown Unknown 2018
Shift Analytics Medidata $195M Unknown Unknown 2018
✓Comparables range $50M to $350M
✓Revenue multiples range 5-6x but likely larger for unknown deals
✓Applying 5x to our 2023E revenue goal of ~$20M supports > $100M exit
Why You Should Invest in OmniLife
20
• Commercialized product –already generating revenue with top U.S. health systems
• Rapid growth – projected 2019 revenues of ~$500k growing to $20M+ in < 5 years
• 25% Immediate ROI - via 25% IA Angel Tax Credit redeemable in cash to all investors
• Vetted by NIH SBIR - $250k Phase I awarded + $2M+ Phase II pending award
• $1M+ committed - Series A Financing (led by BGA Fund IV) already >50% subscribed
• Notable Upside – Exit opportunities in ancillary and highly active M&M markets of secure cloud communications and services provide opportunity for $100M+ exit
• Strong Tailwinds – Gov’t programs geared towards reducing transplant center costs in addition to regulatory changes reinforcing the demand/market for our technology
